용량에 따른 유리체강내 트리암시놀론 주입과 베바시주맙 주입이 안압에 미치는 영향

목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml 주입군(0.1 IVTA군), 베바시주맙 0.05 ml 주입군(0.05 IVB군), 베바시주맙 0.1 ml 주입군(0.1 IVB군) 3집단으로 나눈 후 집단 간과 집단 내에서 주입술 전, 술 후 1일, 술 후 30일의 안압을 비교하였다. 결과: 집단 내 비교...

Full description

Saved in:
Bibliographic Details
Published inDaihan angwa haghoi jabji Vol. 51; no. 11; pp. 1491 - 1498
Main Authors 박종서, Jong Seo Park, 하성우, Sung Woo Ha, 박성배, Seong Bae Park
Format Journal Article
LanguageKorean
Published 대한안과학회 15.11.2010
Subjects
Online AccessGet full text
ISSN0378-6471
2092-9374

Cover

Abstract 목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml 주입군(0.1 IVTA군), 베바시주맙 0.05 ml 주입군(0.05 IVB군), 베바시주맙 0.1 ml 주입군(0.1 IVB군) 3집단으로 나눈 후 집단 간과 집단 내에서 주입술 전, 술 후 1일, 술 후 30일의 안압을 비교하였다. 결과: 집단 내 비교에서 0.05 IVB군과 0.1 IVB군에서는 주입 전 안압에 비해 주입 후 1일 안압이 유의하게 낮았으며(P<0.001, P=0.035), 주입 후 30일에는 주입 후 1일에 비해 유의하게 상승한 결과를 보였다. 0.1 IVTA군의 경우 주입 전에 비해 주입 후 30일에 안압이 유의하게 상승하였다. 집단 간 비교에서는 시술 후 1일째 0.05 IVB군이 0.1 IVTA군보다 유의한 안압 저하를 보였다. 결론: 0.05 IVB군과 0.1 IVB군은 주입술 시행 후 1일에는 안압이 낮아지고 IVTA군은 술 후 30일에 유의한 안압상승을 보였다. <대한안과학회지 2010;51(11):1491-1498> Purpose: To compare intraocular pressure (IOP) changes after intravitreal triamcinolone acetonide versus bevacizumab injection. Methods: IOP was measured in 40 patients who received an intravitreal injection of 0.1 ml triamcinolone and 40 patients who received 2 consecutive intravitreal injections of bevacizumab (0.05 ml and 0.1 ml). Patients were divided into three groups: 0.1 ml triamcinolone group (0.1 IVTA group), 0.05 ml bevacizumab group (0.05 IVB group), and 0.1 ml bevacizumab group (0.1 IVB group). IOPs were compared within groups at different time points (before, 1 day after, and 30 days after the injection) and between groups at the same time points. Results: In the 0.05 IVB and 0.1 IVB groups, IOP at 1 day after injection was significantly lower than before injection (P< 0.01, P = 0.03), and IOP at 30 days after injection was significantly higher than IOP at 1 day after injection (P < 0.01, P < 0.01). In the 0.1 IVTA group, IOP at 30 days after injection was significantly higher than before injection (P = 0.01). Between groups, IOP at 1 day after injection in the 0.05 IVB group was significantly lower than IOP in the 0.1 IVTA group (P = 0.03). Conclusions: IOP was decreased at 1 day after intravitreal bevacizumab injection, whereas in intravitreal triamcinolone acetonide IOP elevation persisted after 1 month. J Korean Ophthalmol Soc 2010;51(11):1491-1498
AbstractList 목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml 주입군(0.1 IVTA군), 베바시주맙 0.05 ml 주입군(0.05 IVB군), 베바시주맙 0.1 ml 주입군(0.1 IVB군) 3집단으로 나눈 후 집단 간과 집단 내에서 주입술 전, 술 후 1일, 술 후 30일의 안압을 비교하였다. 결과: 집단 내 비교에서 0.05 IVB군과 0.1 IVB군에서는 주입 전 안압에 비해 주입 후 1일 안압이 유의하게 낮았으며(P<0.001, P=0.035), 주입 후 30일에는 주입 후 1일에 비해 유의하게 상승한 결과를 보였다. 0.1 IVTA군의 경우 주입 전에 비해 주입 후 30일에 안압이 유의하게 상승하였다. 집단 간 비교에서는 시술 후 1일째 0.05 IVB군이 0.1 IVTA군보다 유의한 안압 저하를 보였다. 결론: 0.05 IVB군과 0.1 IVB군은 주입술 시행 후 1일에는 안압이 낮아지고 IVTA군은 술 후 30일에 유의한 안압상승을 보였다. <대한안과학회지 2010;51(11):1491-1498> Purpose: To compare intraocular pressure (IOP) changes after intravitreal triamcinolone acetonide versus bevacizumab injection. Methods: IOP was measured in 40 patients who received an intravitreal injection of 0.1 ml triamcinolone and 40 patients who received 2 consecutive intravitreal injections of bevacizumab (0.05 ml and 0.1 ml). Patients were divided into three groups: 0.1 ml triamcinolone group (0.1 IVTA group), 0.05 ml bevacizumab group (0.05 IVB group), and 0.1 ml bevacizumab group (0.1 IVB group). IOPs were compared within groups at different time points (before, 1 day after, and 30 days after the injection) and between groups at the same time points. Results: In the 0.05 IVB and 0.1 IVB groups, IOP at 1 day after injection was significantly lower than before injection (P< 0.01, P = 0.03), and IOP at 30 days after injection was significantly higher than IOP at 1 day after injection (P < 0.01, P < 0.01). In the 0.1 IVTA group, IOP at 30 days after injection was significantly higher than before injection (P = 0.01). Between groups, IOP at 1 day after injection in the 0.05 IVB group was significantly lower than IOP in the 0.1 IVTA group (P = 0.03). Conclusions: IOP was decreased at 1 day after intravitreal bevacizumab injection, whereas in intravitreal triamcinolone acetonide IOP elevation persisted after 1 month. J Korean Ophthalmol Soc 2010;51(11):1491-1498
목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml 주입군(0.1 IVTA군), 베바시주맙 0.05 ml 주입군(0.05 IVB군), 베바시주맙 0.1 ml 주입군(0.1 IVB군) 3집단으로 나눈 후 집단 간과 집단 내에서 주입술 전, 술 후 1일, 술 후 30일의 안압을 비교하였다. 결과: 집단 내 비교에서 0.05 IVB군과 0.1 IVB군에서는 주입 전 안압에 비해 주입 후 1일 안압이 유의하게 낮았으며(P<0.001, P=0.035), 주입 후 30일에는 주입 후 1일에 비해 유의하게 상승한 결과를 보였다. 0.1 IVTA군의 경우 주입 전에 비해 주입 후 30일에 안압이 유의하게 상승하였다. 집단 간 비교에서는 시술 후 1일째 0.05 IVB군이 0.1 IVTA군보다 유의한 안압 저하를 보였다. 결론: 0.05 IVB군과 0.1 IVB군은 주입술 시행 후 1일에는 안압이 낮아지고 IVTA군은 술 후 30일에 유의한 안압상승을 보였다. Purpose: To compare intraocular pressure (IOP) changes after intravitreal triamcinolone acetonide versus bevacizumab injection. Methods: IOP was measured in 40 patients who received an intravitreal injection of 0.1 ml triamcinolone and 40 patients who received 2 consecutive intravitreal injections of bevacizumab (0.05 ml and 0.1 ml). Patients were divided into three groups : 0.1 ml triamcinolone group (0.1 IVTA group), 0.05 ml bevacizumab group (0.05 IVB group), and 0.1 ml bevacizumab group (0.1 IVB group). IOPs were compared within groups at different time points (before, 1 day after, and 30 days after the injection) and between groups at the same time points. Results: In the 0.05 IVB and 0.1 IVB groups, IOP at 1 day after injection was significantly lower than before injection (P< 0.01, P = 0.03), and IOP at 30 days after injection was significantly higher than IOP at 1 day after injection (P < 0.01, P < 0.01). In the 0.1 IVTA group, IOP at 30 days after injection was significantly higher than before injection (P = 0.01). Between groups, IOP at 1 day after injection in the 0.05 IVB group was significantly lower than IOP in the 0.1 IVTA group (P = 0.03). Conclusions: IOP was decreased at 1 day after intravitreal bevacizumab injection, whereas in intravitreal triamcinolone acetonide IOP elevation persisted after 1 month. KCI Citation Count: 0
Author Jong Seo Park
Seong Bae Park
Sung Woo Ha
하성우
박성배
박종서
Author_xml – sequence: 1
  fullname: 박종서
– sequence: 2
  fullname: Jong Seo Park
– sequence: 3
  fullname: 하성우
– sequence: 4
  fullname: Sung Woo Ha
– sequence: 5
  fullname: 박성배
– sequence: 6
  fullname: Seong Bae Park
BackLink https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001494214$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNotkMtKw0AUhgdRsNY-gZtsBDeBmcwkM7MU8VIQBOl-yGUiIdpI4sadCoqXjYvGG1UrUkUQLLWLCn2izvQdTLWb83HO__EvzhyYrid1OQVKFuSWyTEl06AEMWWmQyiaBZUsizwIESKMcVQCqX74UM8X-vbaUI2OavcN3Wypt0_d7Q07uTrpGaPL_njPG_qqqc6O1EvL0K8D_XQ6_B4YqttSnXFSnNT7_STRjz1D5-c6z_96v_r6505dNgx9dzy6ac-DmdDdzWRlwjKora3WVjbMza316sryphkzzEzX4gEKAhkSL4Shg-xAOty3C1JsU49iSTjyPN9joWs5GHPXp8SVDoUcB9KCuAyW_mvraShiPxKJG_1xJxFxKpa3a1VBi58gVqiL_2p8mHiJ8JIk9mX9QKaCQAShRTChvJhlsDDxoiwT-2m056aHwmLMgjbHvxiglGI
ContentType Journal Article
Copyright COPYRIGHT(C) KYOBO BOOK CENTRE ALL RIGHTS RESERVED
Copyright_xml – notice: COPYRIGHT(C) KYOBO BOOK CENTRE ALL RIGHTS RESERVED
DBID HZB
Q5X
P5Y
SSSTE
ACYCR
DatabaseName Korea Information Science Society (KISS)
Korean Studies Information Service System (KISS) B-Type
Kyobo Scholar Journals
Scholar(스콜라)
Korean Citation Index
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate 용량에 따른 유리체강내 트리암시놀론 주입과 베바시주맙 주입이 안압에 미치는 영향
The Effect of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection on Intraocular Pressure
EISSN 2092-9374
EndPage 1498
ExternalDocumentID oai_kci_go_kr_ARTI_747118
4010024347924
2882059
GroupedDBID 5-W
5GY
8JR
8XY
ALMA_UNASSIGNED_HOLDINGS
CS3
HZB
Q5X
P5Y
SSSTE
ACYCR
ID FETCH-LOGICAL-k838-a29d1ddef4bf0f615de69c515d7357b73e491bbcb8fa26339ac74ae67093de203
ISSN 0378-6471
IngestDate Tue Nov 21 21:24:07 EST 2023
Thu Jun 19 02:12:23 EDT 2025
Fri Dec 20 02:16:25 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Bevacizumab
Intraocular pressure
Triamcinolone acetonide
Language Korean
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-k838-a29d1ddef4bf0f615de69c515d7357b73e491bbcb8fa26339ac74ae67093de203
Notes The Korean Ophthalmological Society
G704-001025.2010.51.11.017
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_747118
kyobo_bookcenter_4010024347924
kiss_primary_2882059
PublicationCentury 2000
PublicationDate 2010-11-15
PublicationDateYYYYMMDD 2010-11-15
PublicationDate_xml – month: 11
  year: 2010
  text: 2010-11-15
  day: 15
PublicationDecade 2010
PublicationTitle Daihan angwa haghoi jabji
PublicationTitleAlternate 대한안과학회지
PublicationYear 2010
Publisher 대한안과학회
Publisher_xml – name: 대한안과학회
SSID ssib001148891
ssj0064407
Score 1.7446736
Snippet 목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml...
SourceID nrf
kyobo
kiss
SourceType Open Website
Publisher
StartPage 1491
SubjectTerms Bevacizumab
Intraocular pressure
Triamcinolone acetonide
안과학
Title 용량에 따른 유리체강내 트리암시놀론 주입과 베바시주맙 주입이 안압에 미치는 영향
URI https://kiss.kstudy.com/ExternalLink/Ar?key=2882059
https://scholar.kyobobook.co.kr/article/detail/4010024347924
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001494214
Volume 51
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 대한안과학회지, 2010, 51(11), , pp.1491-1498
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Na9RANLQ9eRGlivWjRHBOIbL5njkmu1tqoZ4q7S3MZCfb7cJGti2iJxUUWy8eulqlakWqCIKl9lChv6hJ_4NvJsk2hYIfl-zMmzdv3kdm573hzURRbsUxiRjltu7EZqTbjJg6pS7VCbYhOHA5N01xOHn2rjt9z55ZcBZGRtcqWUurK-x29OjMcyX_Y1WAgV3FKdl_sOyQKACgDPaFJ1gYnn9lY9SsI-Ijn6BmgMgUwkRCPERqmgTZKKiJgu-gAGuysY78HOQivy4ggYkCGzV9gUoc0YQFBLAbCAMUn8IGDKAKBRwIWgLbFdkSAscA0nIQ30JBjt1E2JG0BUTyBMPlDIjhqpSG3YASSEDOpASFRs6cZAXjkifntOT-lGQcpCOISAlAFFL0w-A-C-kICOVUvfMG7SxSkZ3dfkC1RdpeTDraEmVLnfK1LPmWo_lmwRK2hQBmXapMMIMLaGAUFoI-ZiF-2btolpCgNpP02voyTzRxCl2bbcAfOgDmk0SbprLKBUJAeYlQ3a0RmS-Gnp9XlfNLyluXZskZqlf0VRijbCKy4AN-ZU2wIOh37fyrNeUCVtzYW0xUo7IcQfhrVFwbqOKTdX-YjQkhtryY0vYgGB9VRi1Dbn7p8yd-NQTNmAxzp8CHzu8hKLkBfwbCnWUI8LoPE5aAn9brxxU_be6Ccr4IsFQ_ny0XlZFuMq70s3ff0o9r2ZtXarqxm-4cqNnWdvrle7a3f7Q7SJ_uq8frB6I-2MhebqXPH6efttXs82H24dnRz0M13dtOd0ULgNKvb4uW7P2-mg1eZIOBpPvjIPu1ma5vqNnmk-PXO5eUuanmXH1aL742oncxLPrUJC0D1vrYZnEtBj-_xV0Sgbff8izHY57FQZeMRQzH1HQti9DIsykX1x9aLW7WrMvKWC_p8SuKSmwzilzLrLmgKepZjNCYG8RrRZxRj1kTyrjQVng_v08mNCHKhShnQpmU2gtFeC1Ss3k_PGWaCeUmqDXsRp1QXAovfttJ2O2HEPreCcXukoGv_onINeXcyXt5XRlb6a_yG-BXr7BJafPfhVK02Q
linkProvider Korean Association of Medical Journal Editors
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%EC%9A%A9%EB%9F%89%EC%97%90+%EB%94%B0%EB%A5%B8+%EC%9C%A0%EB%A6%AC%EC%B2%B4%EA%B0%95%EB%82%B4+%ED%8A%B8%EB%A6%AC%EC%95%94%EC%8B%9C%EB%86%80%EB%A1%A0+%EC%A3%BC%EC%9E%85%EA%B3%BC+%EB%B2%A0%EB%B0%94%EC%8B%9C%EC%A3%BC%EB%A7%99+%EC%A3%BC%EC%9E%85%EC%9D%B4+%EC%95%88%EC%95%95%EC%97%90+%EB%AF%B8%EC%B9%98%EB%8A%94+%EC%98%81%ED%96%A5&rft.jtitle=Daihan+angwa+haghoi+jabji&rft.au=%EB%B0%95%EC%A2%85%EC%84%9C%2C+%ED%95%98%EC%84%B1%EC%9A%B0%2C+%EB%B0%95%EC%84%B1%EB%B0%B0Jong-seo+Park+MD+Sung-Woo+Ha+MD+Seong-Bae+Park+MD&rft.date=2010-11-15&rft.pub=%EB%8C%80%ED%95%9C%EC%95%88%EA%B3%BC%ED%95%99%ED%9A%8C&rft.issn=0378-6471&rft.volume=51&rft.issue=11&rft.spage=1491&rft.epage=1498&rft.externalDocID=4010024347924
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-6471&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-6471&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-6471&client=summon